Kura Oncology, Inc. reports results for the quarter ended June 30 - Earnings Summary
Kura Oncology, Inc. reports results for the quarter ended June 30 - Earnings Summary
Kura Oncology, Inc. KURA.OQ reported a quarterly adjusted loss of 77 cents per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -75 cents. The mean expectation of fourteen analysts for the quarter was for a loss of 88 cents per share. Wall Street expected results to range from $-1.02 to -75 cents per share.
Revenue rose 36.5% to $20.87 million from a year ago; analysts expected $21.42 million.
Kura Oncology, Inc.'s reported EPS for the quarter was a loss of 77 cents.
The company reported a quarterly loss of $68.33 million.
Kura Oncology, Inc. shares had fallen by 9.5% this quarter and lost 4.4% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 1.8% in the last three months.
In the last 30 days, there have been no negative revisions of earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Kura Oncology, Inc. is $28.00, about 64.5% above its last closing price of $9.93
This summary was machine generated from LSEG data August 12 at 09:00 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | -0.88 | -0.77 | Beat |
Mar. 31 2026 | -0.63 | -0.83 | Missed |
Dec. 31 2025 | -0.48 | -0.92 | Missed |
Sep. 30 2025 | -0.85 | -0.85 | Met |